• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

    4/29/25 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email

    WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a virtual KOL investor event on Friday, May 9 at 1:00 PM ET / 10:00 AM PT to provide an overview of anemia of myelofibrosis (MF) and discuss the evolving treatment landscape for this disease. The event will also include an overview of Disc's clinical data and development plans for DISC-0974 in MF anemia.

    Intended for investors and other interested audiences, the virtual event will feature presentations from leading experts on myeloproliferative neoplasms (MPNs), including MF. The KOL speakers will provide an overview of MF anemia, its epidemiology, pathogenesis, and impact on patients, then discuss the current and emerging therapeutic landscape for MF and highlight the clear unmet need for anemia-focused treatments. Invited speakers include:

    • Dr. Aaron Gerds, M.D., M.S., a hematologist-oncologist at Cleveland Clinic and associate professor at Case Western University School of Medicine, where he runs the cancer center's Clinical Research Office. Dr. Gerds has been a principal investigator in various clinical trials for MPNs.
    • Dr. Prithviraj Bose, M.D., a professor at MD Anderson Cancer Center with a focus on MPNs. Dr. Bose has been a leader in multiple clinical trials in myelofibrosis.

    Members of Disc's leadership team will review the therapeutic rationale for DISC-0974, summarize clinical data from the Phase 1b trial of DISC-0974 in MF anemia originally presented at the 2024 American Society of Hematology (ASH) annual meeting, discuss the design for its ongoing Phase 2 trial, and reiterate expected timing for an interim Phase 2 data readout in 2025. Management will also provide a view of the expected market opportunity and positioning for DISC-0974 in MF anemia.

    A live webcast of the event will be available in the Events and Presentations section of the Investor Relations page of Disc's website (https://ir.discmedicine.com/). A webcast replay will be available after the live presentation and will be accessible for 90 days. Please register for the event on the Events and Presentations page of Disc's website (https://edge.media-server.com/mmc/p/5c72d8fu).

    About DISC-0974

    DISC-0974 is an investigational monoclonal antibody (mAb) targeting a BMP-signaling co-receptor called hemojuvelin (HJV) and is designed to suppress hepcidin production and increase serum iron levels in patients suffering from anemia of inflammation. DISC-0974 was in-licensed by Disc from AbbVie in 2019. Anemia of inflammation arises from abnormally elevated hepcidin and is the second most common form of anemia, affecting millions of patients in the US across numerous diseases, such as chronic kidney disease, myelofibrosis, cancer, autoimmune diseases, and other conditions with an inflammatory component. Disc has established clinical proof-of-mechanism of DISC-0974 in a Phase 1 trial of healthy volunteers, completed a Phase 1b clinical trial in patients with myelofibrosis and anemia, and initiated a Phase 2 clinical trial of DISC-0974 in patients with MF anemia, as well as a Phase 1b/2a clinical trial of DISC-0974 in patients with chronic kidney disease and anemia who are not receiving dialysis.

    DISC-0974 is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide.

    About Anemia of Myelofibrosis

    Myelofibrosis (MF) is a rare, chronic blood cancer that currently affects an estimated 25,000 patients in the United States alone. Severe, progressive, and treatment resistant anemia is a primary clinical manifestation of MF. At diagnosis, over 80% of MF patients have anemia, which progressively worsens and ultimately renders the majority of patients dependent on chronic red blood cell transfusions. Recent studies have shown hepcidin to be a key molecular driver of anemia in myelofibrosis. Hepcidin is elevated by approximately 12-fold in MF patients, and is correlated with disease severity, anemia, and the need for red blood cell transfusions.

    About Disc Medicine

    Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

    Disc Cautionary Statement Regarding Forward-Looking Statements        

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to the projected timeline for an interim data readout from its ongoing Phase 2 clinical trial of DISC-0974 in anemia of MF. The use of words such as, but not limited to, "believe," "expect," "estimate," "project," "intend," "future," "potential," "continue," "may," "might," "plan," "will," "should," "seek," "anticipate," or "could" or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc's current beliefs, expectations and assumptions regarding the future of Disc's business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements

    Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc's capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc's product candidates; Disc's plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc's planned preclinical studies and clinical trials; the timing of the availability of data from Disc's clinical trials; Disc's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc's preclinical studies and clinical trials and the risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc's filings with the Securities and Exchange Commission, including in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

    Media Contact

    Peg Rusconi

    Deerfield Group

    [email protected]

    Investor Relations Contact

    Christina Tartaglia

    Precision AQ

    [email protected]



    Primary Logo

    Get the next $IRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    8/22/2024$75.00Overweight
    Wells Fargo
    4/1/2024$40.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $IRON
    SEC Filings

    See more
    • Disc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      6/13/25 5:05:09 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Disc Medicine Inc.

      SCHEDULE 13G - Disc Medicine, Inc. (0001816736) (Subject)

      5/12/25 10:44:44 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.

      SCHEDULE 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      5/12/25 10:28:12 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

      Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

      6/12/25 7:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine to Participate in Upcoming Investor Conferences

      WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5th at 10:30 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th at 1:20 p.m. ET. Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and

      5/28/25 4:01:00 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

      Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

      5/14/25 9:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

      Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

      11/12/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

      WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

      10/23/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

      WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo

      9/19/24 8:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 5:44:55 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 4:33:10 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Disc Medicine Inc.

      SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

      11/8/24 10:52:39 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 8:00:05 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:27:54 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:19:39 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on Disc Medicine with a new price target

      Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

      6/11/25 7:53:18 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Disc Medicine

      TD Cowen initiated coverage of Disc Medicine with a rating of Buy

      2/27/25 6:22:05 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Disc Medicine from Equal-Weight to Overweight and set a new price target of $85.00

      11/5/24 7:18:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Financials

    Live finance-specific insights

    See more
    • Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

      Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

      6/12/25 7:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

      Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

      5/14/25 9:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

      Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

      1/21/25 7:45:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director White William Richard

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:32:13 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ratcliffe Liam

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:29:57 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nicholson Donald William

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:25:45 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care